OncoPharm
John Bossaer
Add to My Podcasts
Episodes
About
Reviews
Promote
Polatuzumab-vedotin
13 minutes
Posted Jun 13, 2019 at 8:44 pm.
0:00
13:29
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
A newly approved drug for relapsed/refractory diffuse large B-cell lymphoma is discussed as well as PBR.
Previous
ASCO '19
Next
Pembrolizumab Nets 2 More Approvals
← See all 273 episodes of OncoPharm
